AVXL vs BIIB · $247.4M cap vs P/E 21, rev $9.89B
Anavex Life Sciences Corp (AVXL) versus Biogen Inc (BIIB) — a side-by-side from cached financials, not a winner call.
Anavex Life Sciences Corp (AVXL) is a biotechnology company listed on NASDAQ.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
AVXL does not have a complete income-statement cache yet.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
AVXL currently screens at market cap $247.4M. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Not investment advice. Open the AVXL and BIIB stock pages for the full models.
Not investment advice.